These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24125776)

  • 1. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
    Shen J; Song G; An M; Li X; Wu N; Ruan K; Hu J; Hu R
    Biomaterials; 2014 Jan; 35(1):316-26. PubMed ID: 24125776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
    Li C; Hu J; Li W; Song G; Shen J
    Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
    Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
    Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
    J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
    Neukirchen J; Meier A; Rohrbeck A; Garcia-Pardillos G; Steidl U; Fenk R; Haas R; Kronenwett R; Rohr UP
    Cancer Gene Ther; 2007 Apr; 14(4):431-9. PubMed ID: 17235352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity.
    Luo Z; Hu Y; Cai K; Ding X; Zhang Q; Li M; Ma X; Zhang B; Zeng Y; Li P; Li J; Liu J; Zhao Y
    Biomaterials; 2014 Sep; 35(27):7951-62. PubMed ID: 24930850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
    Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
    Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
    Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction.
    Rong J; Li P; Ge Y; Chen H; Wu J; Zhang R; Lao J; Lou D; Zhang Y
    Colloids Surf B Biointerfaces; 2020 Feb; 186():110674. PubMed ID: 31855686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of proteasome inhibitors in the treatment of lung cancer.
    Bunn PA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
    Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino Acid-functionalized hollow mesoporous silica nanospheres as efficient biocompatible drug carriers for anticancer applications.
    Ezzati N; Mahjoub AR; Abolhosseini Shahrnoy A; Syrgiannis Z
    Int J Pharm; 2019 Dec; 572():118709. PubMed ID: 31629730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
    Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
    Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
    Fanucchi MP; Fossella FV; Belt R; Natale R; Fidias P; Carbone DP; Govindan R; Raez LE; Robert F; Ribeiro M; Akerley W; Kelly K; Limentani SA; Crawford J; Reimers HJ; Axelrod R; Kashala O; Sheng S; Schiller JH
    J Clin Oncol; 2006 Nov; 24(31):5025-33. PubMed ID: 17075122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
    Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating bortezomib into the treatment of lung cancer.
    Davies AM; Lara PN; Mack PC; Gandara DR
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
    Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
    Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hollow mesoporous silica nanoparticles facilitated drug delivery via cascade pH stimuli in tumor microenvironment for tumor therapy.
    Liu J; Luo Z; Zhang J; Luo T; Zhou J; Zhao X; Cai K
    Biomaterials; 2016 Mar; 83():51-65. PubMed ID: 26773665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.